{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:15Z","timestamp":1760142555139,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.biopha.2009.11.001","type":"journal-article","created":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T09:33:41Z","timestamp":1260437621000},"page":"83-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"64","author":[{"given":"D.","family":"Machover","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Delmas-Marsalet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ulusakarya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Gumus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Fr\u00e9noy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Saffroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Innominato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Almohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Brahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Haydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2009.11.001_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1012501305214","article-title":"Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma","volume":"12","author":"Machover","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0753-3322(89)90004-8","article-title":"Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane) platinum (II): New experimental data","volume":"43","author":"Tashiro","year":"1989","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0753-3322(89)90003-6","article-title":"Oxalatoplatinum or l-OHP, a third generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum","volume":"43","author":"Math\u00e9","year":"1989","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2009.11.001_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1008310708853","article-title":"Preliminary results on the activity of oxaliplatin (L-OHP) in refractory\/recurrent non-Hodgkin's lymphoma patients","volume":"10","author":"Germann","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib6","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1200\/JCO.2004.00.8532","article-title":"Phase\u00a0II study of oxaliplatin for tretment of patients with mucosa-associated lymphoid tissue lymphoma","volume":"23","author":"Raderer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/1097-0142(19811101)48:9<1927::AID-CNCR2820480902>3.0.CO;2-#","article-title":"Pase II trial of cis-diamminedichloroplatinum (II) in advanced malignant lymphoma: A study of the Cancer and Leukemia Group B","volume":"48","author":"Cavalli","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2009.11.001_bib8","first-page":"1605","article-title":"Phase\u00a0II evaluation of cis-diamminedichloroplatinum (II) in lymphomas: A Southwest Oncology Group study","volume":"63","author":"Rossof","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.biopha.2009.11.001_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase\u00a0II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2001.03181.x","article-title":"An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma","volume":"115","author":"Chau","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.biopha.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019\u00e9tude des lymphomes de l\u2019adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An east German hematology and oncology study group","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib17","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib18","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma in patients both with and without riuximab during induction: Results of a prospective randomized phase\u00a03 intergroup trial","volume":"108","author":"Van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"(chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2009.11.001_bib20","series-title":"World Health Organization Classification of Tumours","article-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.biopha.2009.11.001_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib22","first-page":"471","article-title":"Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B-cell malignancies","volume":"9","author":"Aubin","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2009.11.001_bib23","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1073\/pnas.85.13.4869","article-title":"Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease","volume":"85","author":"Crescenzi","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopha.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2144\/98256cr05","article-title":"Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes","volume":"25","author":"D\u00f6lken","year":"1998","journal-title":"Biotechniques"},{"key":"10.1016\/j.biopha.2009.11.001_bib25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib26","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","article-title":"The clinical significance of molecular response in indolent follicular lymphomas","volume":"91","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib27","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2009.11.001_bib28","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy, 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2009.11.001_bib29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the university of Texas M.D. Anderson Cancer Center","volume":"24","author":"Qi Liu","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209002479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209002479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:45:25Z","timestamp":1760093125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332209002479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0753332209002479"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2009.11.001","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2009.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}